Common use of Introduction and Statement of Policy Clause in Contracts

Introduction and Statement of Policy. The National Institutes of Health (NIH) has established NIH-designated data repositories (e.g., database of Genotypes and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH under the NIH Genomic Data Sharing (GDS) Policy. Because the volume of human genomic and phenotypic data contained in these repositories is substantial and, in some instances, potentially sensitive (e.g., data related to the presence or risk of developing particular diseases or conditions and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the NCI that approved users of controlled-access datasets obtained through this DAR recognize any restrictions on data use established by the submitting institution through the Institutional Certification and stated on the dbGaP study page. Definitions of terminology used in this document are found in the Appendix. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution as represented by the Institutional Signing Official designated through the eRA Commons system (the “Requester”), and the relevant NIH Institute or Center (IC). The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee (DAC) approval notification.

Introduction and Statement of Policy. The National Institutes of Health Institute on Aging (NIHNIA) has established NIH-designated the NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) as a resource to serve as a repository for many types of data repositories (e.g., database of Genotypes generated by NIA supported grants and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH cooperative agreements and/or NIA funded biological samples. NIAGADS operates under the NIH Genomic Genomics Data Sharing Policy (GDS) and the NIA Genetics of Alzheimer’s Disease Data Sharing Policy. Because the volume of human genomic and phenotypic data contained in these repositories is substantial andNIAGADS is, in some instances, potentially sensitive (information, e.g., data related to the presence or risk of developing particular diseases or conditions Alzheimer’s Disease and related neurodegenerative disorders, and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the NCI National Institute on Aging (NIA) that approved users of controlled-access datasets obtained through this DAR NIAGADS Data Access Request (DAR) recognize any restrictions on data use established by the submitting institution through the Institutional Certification and stated on the dbGaP study page. NIAGADS website xxxxx://xxx.xxxxxxx.xxx/. Definitions of terminology used in this document are found in the Appendixsection 14. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution as represented by the Institutional Signing Official designated through the eRA Commons system (the “Requester”), and the relevant NIH Institute or Center (IC)NIAGADS. The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee (DAC) NIAGADS approval notification.

Introduction and Statement of Policy. The National Institutes of Health Institute on Aging (NIHNIA) has established NIH-designated the NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) as a resource to serve as a repository for many types of data repositories (e.g., database of Genotypes generated by NIA supported grants and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH cooperative agreements and/or NIA funded biological samples. NIAGADS operates under the NIH Genomic Genomics Data Sharing Policy (GDS) Policyand the NIA Genomics of Alzheimer’s Disease Data Sharing Policy . Because the volume of human genomic and phenotypic data contained in these repositories is substantial andNIAGADS is, in some instances, potentially sensitive (information, e.g., data related to the presence or risk of developing particular diseases or conditions Alzheimer’s Disease and related neurodegenerative disorders, and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the NCI National Institute on Aging (NIA) that approved users of controlled-access datasets obtained through this DAR NIAGADS Data Access Request (DAR) recognize any restrictions on data use established by the submitting institution through the Institutional Certification and stated on the dbGaP study page. NIAGADS website xxxxx://xxx.xxxxxxx.xxx/. Definitions of terminology used in this document are found in the Appendix. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution as represented by the Institutional Signing Official designated through the eRA Commons system (the “Requester”), and the relevant NIH Institute or Center (IC)NIAGADS. The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee (DAC) NIAGADS approval notification.

Introduction and Statement of Policy. The National Institutes of Health (NIH) has established NIH-designated data repositories (e.g., database of Genotypes and Phenotypes (dbGaP), Sequence Read Archive (SRA), NIH Established Trusted Partnerships) for securely storing and sharing controlled-access human data submitted to NIH under the NIH Genomic Data Sharing (GDS) Policy. Because the volume of human genomic and phenotypic data contained in these repositories is substantial and, in some instances, potentially sensitive (e.g., data related to the presence or risk of developing particular diseases or conditions and information regarding family relationships or ancestry), data must be shared in a manner consistent with the research participants’ informed consent, and the confidentiality of the data and the privacy of participants must be protected. Access to human genomic data will be provided to research investigators who, along with their institutions, have certified their agreement with the expectations and terms of access detailed below. It is the intent of NIH and the NCI NLM that approved users of controlled-access datasets obtained through this DAR recognize any restrictions on data use established by the submitting institution through the Institutional Certification and stated on the dbGaP study page. Definitions of terminology used in this document are found in the Appendix. The parties to this agreement include: the Principal Investigator (PI) requesting access to the genomic study dataset (an “Approved User”), the PI’s home institution as represented by the Institutional Signing Official designated through the eRA Commons system (the “Requester”), and the relevant NIH Institute or Center (IC). The effective date of this agreement shall be the Project Approval Date, as specified on the Data Access Committee (DAC) approval notification.